The Potential of Gene Therapy for AADC Deficiency: Paul Wuh-Liang Hwu, MD, PhD

Video

The professor from National Taiwan University Hospital discussed the mechanism of gene therapy in AADC deficiency.

"In terms of AADC deficiency... we inject the virus into the putamen and the virus delivers the DNA to the cells. So the cell will then express the gene we want and the patient starts to synthesize dopamine again, and then they get improvement in their symptoms."

Treatment with the novel gene therapy PTC-AADC leads to durable developmental, motor, and cognitive improvements in children with aromatic L-Amino acid decarboxylase (AADC) deficiency, according to updated data from a 5-year analysis of 3 clinical trials announced by PTC Therapeutics.1,2

Children treated with the gene therapy reached milestones such as holding up their heads and sitting or standing with support as early as 3 months after treatment. They also had improved communication skills via Bayley-3 scores. These data were presented at the 50th Child Neurology Society (CNS) Annual Meeting, September 29 to October 2.

GeneTherapyLive spoke with investigator Paul Wuh-Liang Hwu, MD, PhD, professor, pediatrics, National Taiwan University Hospital, to learn more about the potential of using gene therapy to cure AADC deficiency. He explained that the mechanism of gene therapy is simple in such a disease.

REFERENCES
1. Results show long-lasting and holistic improvements in children with AADC deficiency treated with PTC-AADC gene therapy. News release. PTC Therapeutics. September 29, 2021. https://www.prnewswire.com/news-releases/results-show-long-lasting-and-holistic-improvements-in-children-with-aadc-deficiency-treated-with-ptc-aadc-gene-therapy-301387687.html
2. Hwu PWL, Kiening K, Anselm I, et al. Gene therapy in the putamen for curing AADC deficiency and Parkinson's disease. EMBO Mol Med. 2021;13:e14712. doi: 10.15252/emmm.202114712

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.